40887-80-7

Basic information

• Product Name: 3-bromophenylhydrazine
• Synonyms: 1-(3-Bromophenyl)hydrazine;(3-Bromophenyl)
• CAS NO: 40887-80-7
• Molecular Formula: C6H7BrN2
• Molecular Weight: 187.05
• EINECS: 255-130-2
• Product Categories: amine|alkyl bromide
• Mol File: 40887-80-7.mol

Chemical Properties

• Boiling Point: 174-176 °C(Press: 20 Torr)
• Appearance: /
• Density: 1.666±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.91±0.10(Predicted)
• CAS DataBase Reference: 3-bromophenylhydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromophenylhydrazine(40887-80-7)
• EPA Substance Registry System: 3-bromophenylhydrazine(40887-80-7)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 40887-80-7(Hazardous Substances Data)

Upstream product

• 591-19-5 m-Bromoaniline 
• 7647-01-0 hydrogenchloride 
• 20893-74-7 3-bromophenyldiazonium chloride 
• 27246-81-7 3-bromophenylhydrazine hydrochloride 

Downstream Products

• 78863-98-6 5-bromo-1,2,3,4-tetrahydrocarbazole 
• 78863-99-7 7-bromo-2,3,4,9-tetrahydro-1H-carbazole 
• 859960-54-6 2-(3-bromo-phenyl)-4-phenyl thiosemicarbazide 
• 65837-38-9 6-bromo-3-methyl-2-phenyl-indole 
• 113752-85-5 N-(3-bromo-phenyl)-N'-trityl-hydrazine 
• 33732-13-7 N-(3-Bromo-phenyl)-N'-[1-(4-bromo-phenyl)-eth-(Z)-ylidene]-hydrazine 
• 33909-89-6 N-(3-Bromo-phenyl)-N'-[1-(4-bromo-phenyl)-prop-(Z)-ylidene]-hydrazine 
• 71856-56-9 5-amino-1-(3-bromophenyl)-1H-pyrazole-4-carbonitrile 

Relevant articles and documents

3-bromophenylhydrazine phosphate preparation method

The invention relates to a 3-bromophenylhydrazine phosphate preparation method. The method comprises the steps of diazotization, reduction, purification and salt formation. In the diazotization and reduction steps, a reaction liquid is kept strongly acidic with concentrated hydrochloric acid, such that smooth and complete reactions are ensured. In the reduction step, zinc powder-concentrated hydrochloric acid is adopted as a reducing agent for replacing sodium thiosulfate, sodium bisulfite, stannous chloride-hydrochloric acid and the like, such that reduction performance is good, yield is high, and reaction time is shortened. Impurities such as zinc hydroxide produced in the reaction are easy to remove, such that product impurity amount is low, and product purity is high. In the salt formation step, acetone is used for leaching, such that product purity is improved, and product appearance is ensured. The preparation method has the advantages of stable and reliable process, easy operation, and high product purity (product content is no lower than 99.2% as a result of high-performance liquid chromatography). A product yield is no lower than 42%. The method can completely satisfy market demands on 3-bromophenylhydrazine phosphate.

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

NOVEL COMPOUNDS FOR ORGANIC ELECTRONIC MATERIAL AND ORGANIC ELECTRONIC DEVICE USING THE SAME

The present invention relates to novel compounds for organic electronic material, and organic electronic devices and organic solar cells using the same. The compounds for organic electronic material may be included in a hole transport layer, electron transport layer or hole injection layer, or may be used as host or dopant. With good luminous efficiency and excellent life property of the material, they may be used to manufacture OLEDs having very good operation life.

CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, formula (I) are useful as kinase modulators, including Btk modulation.

Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold

HIV-1 integrase (IN), one of the essential enzymes in HIV infection, has been validated as a target for HIV treatment. While more than 20 drugs have been approved by the FDA to treat HIV/AIDS, only one drug, Raltegravir (1), was approved as an IN inhibitor. The rapid mutation of the virus, which leads to multidrug resistant HIV strains, presents an urgent need to find potent compounds that can serve as second-generation IN inhibitors. The pyrazolone scaffold, predicted by a computational modeling study using GS-9137(2) as a pharmacophoric model, has shown to inhibit the IN catalytic activities in low micromolar range. We have synthesized various analogs based on the pyrazolone scaffold and performed SAR studies. This paper will showcase the up-to-date result of this scaffold as a promising HIV-1 IN inhibitor.

1-(3′-[125I]iodophenyl)-3-methy-2-pyrazolin-5-one: Preparation, solution stability, and biodistribution in normal mice

3-Methyl-1-phenyl-2-pyrazolin-5-one (edaravone, 1), known as a potent free radical scavenger, has been developed as a medical drug for the treatment of acute cerebral infarction. With the aim of developing radiotracers for imaging free radicals in vivo, 1-(3′-[125I]iodophenyl)-3-methy-2- pyrazolin-5-one (125I-2) was synthesized by two methods, via isotopic exchange and interhalogen exchange under solvent-free conditions, in which iodo- and bromo-derivatives were used as labeling precursors, respectively. After HPLC purification, 125I-2 was obtained in modest isolated radiochemical yields (ca. 20%) with high radiochemical purities by both methods. The former gave specific activities of 0.2-0.6 kBq/μmol, whereas the latter approach achieved specific activities of more than 0.14 GBq/μmol. On attempting to prepare an injectable formulation for 125I-2 with high specific activity, its radiochemical purities dropped to about 60-70%. Unlabeled analog 2 was found to have lipophilic and antioxidant properties similar to edaravone. Intravenous injection of 125I-2 with low specific radioactivity into normal mice showed signs of distribution profiles similar to reported results for 14C-labeled edaravone in normal rats.

Synthesis and adenosine receptor affinity of a series of pyrazolo[3,4-d]pyrimidine analogues of 1-methylisoguanosine

Pyrazolo[3,4-d]pyrimidines are pyrazolo analogues of purines. They have been shown to be a general class of compounds which exhibit A1 adenosine receptor affinity. Two series of pyrazolo[3,4-d]pyrimidine analogues of 1-methylisoguanosine have been synthesized. The first involved substitution of the N1-position while the second involved substitution of the N5-position. Both alkyl and aryl substituents were examined. All compounds were tested for A1 adenosine receptor affinity by using a (R)-[3H]-N6-(phenylisopropyl)adenosine binding assay. The 3-chlorophenyl group showed the greatest activity in the N1-position and the butyl group produced the greatest activity in the N5-position. Combination of the best substituent in each of these positions enhanced the overall activity. The most potent compound was 4-amino-5-N-butyl-1-(3-chlorophenyl)-1H-pyrazolo[3,4-d] pyrimidin-6(5H)-one with an IC50 of 6.4 X 10-6 M. Selectivity at the receptor subclasses was examined by performing an A2 adenosine receptor affinity assay with [3H]CGS 21680. This series of compounds were slightly less potent at A2 receptors. 4-Amino-5-N-butyl-1-(3-chlorophenyl)-1H-pyrazolo[3,4-d] pyrimidin-6(5H)-one was the most potent compound with an IC50 of 19.2 X 10-6 M.

Pyrazol-4-acetic acid compounds

Pyrazol-4-acetic acid compounds, such as substituted pyrazol-4-acetic acid, its esters, amides, nitriles and their pharamaceutically acceptable salts and method for the preparation of these compounds are disclosed. The novel compounds are useful analgesics, anti-inflammatory, and antipyretics.